Ketamine and phenobarbital do not reduce the evoked-potential enhancement induced by electroconvulsive shock seizures in the rat.
Electroconvulsive shock (ECS) seizures provide an animal analog of electroconvulsive therapy (ECT). Repeated ECS seizures cause a long-lasting, and perhaps permanent, enhancement of entorhinal-dentate evoked potentials (EPs) in the rat. Recently it has been reported that ketamine protects against ECS-induced EP enhancement. The present study was designed to replicate these findings and to extend them by incorporating a phenobarbital group (to control for ketamine's partial diminution of seizures) and an animal test of antidepressant activity (the Porsolt test). Unexpectedly, we found that neither ketamine nor phenobarbital protected against ECS-induced enhancement of EPs. Both, however, diminished the 'therapeutic' effects of ECS, as modeled by the Porsolt test. These data suggest that the use of ketamine would not eliminate the unwanted effects of ECT and that it might diminish ECT's therapeutic benefits.
Gombos
Z
Z
Bloorview Epilepsy Program, University of Toronto, ON, Canada.
Mendonça
A
A
Cottrell
G A
GA
Burnham
W M
WM
D000818:Animals; D004597:Electroshock; D005071:Evoked Potentials / Q000187:drug effects; D007649:Ketamine / Q000494:pharmacology*; D008297:Male; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010634:Phenobarbital / Q000494:pharmacology*; D051381:Rats; D020318:Rats, Long-Evans; D012640:Seizures / Q000503:physiopathology*
D018696:Neuroprotective Agents; D007649:Ketamine; D010634:Phenobarbital